The document discusses the current and future potential applications of PET/MR imaging in neurodegenerative diseases. PET/MR combines the molecular imaging capabilities of PET with the high spatial resolution of MRI. It allows simultaneous acquisition of PET and MRI data. Current applications include detection of amyloid plaques and dopamine deficits. Emerging tracers may image tau and alpha-synuclein. Novel MRI techniques like diffusion tensor imaging and arterial spin labeling also show promise. Combined PET/MR could become a routine first-line tool for diagnosis and may aid basic research into neurodegeneration.
In this presentation, i have explained different modalities available for radiological evaluation of cns tumors. How to approach to a radiographic image and how to approach to a patient of cns tumors radiologically.
pediatirc neuroimaging , primer for pediatricians interested in neuroimaging and basic stuff for radiologists.
included examples of normal and abnormal.
when to do what imaging
In this presentation, i have explained different modalities available for radiological evaluation of cns tumors. How to approach to a radiographic image and how to approach to a patient of cns tumors radiologically.
pediatirc neuroimaging , primer for pediatricians interested in neuroimaging and basic stuff for radiologists.
included examples of normal and abnormal.
when to do what imaging
This pdf is about the Positron Emission Tomography (PET) technique.
For more details visit on YouTube; @SELF-EXPLANATORY;
PET; https://youtu.be/rlwGbFGS6wg
Thanks...!
Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain in...IntesarAldweri
Traumatic brain injury (TBI) is one of the leading causes of death worldwide, and mild traumatic brain injury (mTBI) is the most common traumatic injury.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common chronic inflammatory neuropathy. CIDP is diagnosed according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria
https://www.youtube.com/watch?v=AYEhL1LdONY
Chair, Tammie L.S. Benzinger, MD, PhD, Jerome A. Barakos, MD, and Gregory S. Day, MD, MSc, MSCI, FAAN, prepared useful Practice Aids pertaining to Alzheimer's disease for this CME activity titled “The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Management: Is Radiology Prepared for New Challenges?” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/2YzMICB. CME credit will be available until February 14, 2023.
Similar to PET/MR imaging in neurodegenerative diseases (20)
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
1. The Current And Future Potential
Applications Of PET/MR Imaging
In Neurodegenerative Diseases
By
Dr. Walid Rezk, M.D.
Lecturer of Radiodiagnosis
Ain Shams University
2. Neurodegenerative disorders such as Alzheimer
disease are among today’s most alarming health
problems in our aging society.
The clinical assessment of neurodegenerative
disorders benefits from recent innovations in the field
of imaging technology.
These innovations include emerging tracers for
molecular imaging of neuro-degenerative pathology
and the introduction of novel integrated PET/MR
imaging instruments.
Introduction
3. Neurodegenerative diseases are characterized by a
progressive and chronic loss of neural tissue in cognitive,
motor, sensory, and other brain systems.
This entity of diseases includes:
o Dementias
o Parkinsonian syndromes including movement diseases
such as multisystem atrophies (MSA), cortical-basal
degeneration (CBD), and progressive supranuclear
palsy (PSP)
o Huntington disease (HD)
o Amyotrophic lateral sclerosis (ALS)
o Prion diseases like Creutzfeldt-Jakobdisease (CJD)
Neurodegenerative disorders
4. In daily routine, most neurodegenerative diseases are
diagnosed by a combination of clinical testing
together with biomarkers, like brain imaging or
cerebrospinal fluid analysis.
In brain imaging of neurodegenerative disease, MRI
represents the standard tool. This is based on the
high spatial resolution and the high soft tissue
contrast this modality offers as well as the rather
specific findings in at least some movement disorders
such as MSA and PSP.
5. Often MRI is employed in suspected
neurodegenerative diseases to exclude other non-
neurodegenerative causes for the symptoms
observed, like vascular disease, brain tumors, and
traumatic or inflammatory brain changes.
In addition, certain brain atrophy patterns may
support the clinical diagnosis of distinct
neurodegenerative diseases.
6. Brain PET has also been used over many years to
diagnose neurodegenerative diseases.
The main advantage of PET over MRI lies in its higher
sensitivity to detect pathologies on a molecular level,
which at least in principle permits more sensitive or
even earlier diagnoses, because these diseases start
with pathobiochemical processes that only lead to
morphologic changes visible on MRI after a certain
time period.
8. It is evident that [18F]FDG, which is transported into
intracellular space by glucose 1 transporters followed
by phosphorylation via the hexokinase reaction, is the
most often employed PET tracer in this regard.
[18F]FDG represents a universal marker of neuronal
and synaptic integrity with relatively disease-specific
uptake reduction patterns as for example:
10. o Frontotemporal lobar
degeneration (FTLD) in
which, depending on its
subtype, mainly frontal
region or temporal
region or both exhibit
[18 F]FDG uptake
reductions.
11. o Parkinsonism: [18F]FDG-PET allows discrimination
between primary PD and atypical parkinsonian
syndromes, as major glucose consumption deficits
being only found in the latter.
o HD: mainly showing striatal uptake reduction
o ALS: showing variable uptake reduction patterns
depending on the ALS subtypes.
12. CJD: showing patchy uptake reductions of different
patterns throughout the cortex and subcortical
structures.
13. Apart from [18F]FDG, two groups of more disease-
specific PET tracers are currently available in clinical
routine:
1. Amyloid plaque tracers:
In AD, β-amyloid plaques, one of the
histopathologically hallmarks of the disease,
recently became traceable by PET tracers, like [18F]
florbetapir, [18F] florbetaben, or [18F] flutemetamol.
These tracers are now approved for clinical use and
are currently employed to show or exclude brain
amyloid load in mild cognitive impairment (MCI), and
early-onset clinical presentation of AD-like dementia.
14. 2. PET tracers that target different components of
dopaminergic transmission:
Dopamine precursor tracer 3,4-dihydroxy-6-[18F]-
fluorol-phenylalanine ([18F] FDOPA)
The presynaptic dopamine transporter (DAT)-
targeting [18F] fluoropropyl carbomethoxy
iodophenylnortropane (FP-CIT)
Both are used for clinical routine purposes to
diagnose parkinsonian syndromes
15. In the scan of a disease-free brain, made with [18F]-
FDOPA PET (left image), the red and yellow areas show
the dopamine concentration in a normal putamen.
Compared with that scan, a similar scan of a
Parkinson’s patient (right image) shows a marked
dopamine deficiency in the putamen.
17. Disease Typical MRI Sequences
Alzheimer disease T2 FLAIR and T1 3D GRE
FTLD FLAIR and T1 3D GRE
Vascular dementia FLAIR, T2*/SWI, and DWI
DLB FLAIR and T1 3D GRE
Parkinson disease T1, T2 multiplanar, and T2*/SWI
Atypical parkinsonian syndromes T1, T2 multiplanar, and T2*/SWI
Huntington disease T1, T2, and T2*/SWI
ALS T1 and T2
CJD DWI, FLAIR, T1, and T2
Current Clinical Routine MRI Sequences to Image
Neurodegenerative Diseases
18. The routine MR imaging may reveal specific pattern of
atrophy as in:
AD: Temporal atrophy patterns according to
established scores (Scheltens score)
20. Cerebellar MSA (formerly known as olivopontine
cerebellar atrophy): pontine and cerebellar atrophy
patterns combined with distinctive signs of pontine
neurodegeneration (hot cross bun sign)
23. Parkinsonian MSA (formerly known as MSA-
striatonigral degeneration): periputaminal gliosis
CBD: unilateral atrophy of the primary motor cortex
together with cortico-spinal tract degeneration
24. Diffusion-weighted MRI may show typical signal
changes of the basal ganglia and cortex in CJD with
greater visibility than on T2-weighted images owing
to restricted diffusion with extracellular edema
26. Taking the aforementioned status and advantages of
both PET and MR to image neurodegenerative
diseases, it was a logical early step to clinically test
the potential of combined PET/MRI technology in
improving and simplifying neurodegeneration
imaging.
27. One of the main technical challenges of integrated
PET/MRI is to find a reliable substitute for the standard
transmission-based (CT or line sources) attenuation
correction (AC) of the PET data, a technique which is not
available within combined PET/MRI systems.
In the current PET/MRI systems, AC of the PET data is
mainly accomplished by using a 2-point Dixon MR
sequence that segments tissues into four classes (lung, air,
fat, and soft tissue) and is in some systems supplemented
or substituted by an ultrashort echo time (UTE) sequence
that provides additional bone contrast or segmentation.
28. An MR localizer precedes an approximately 20-
minutes data acquisition interval in which a PET
emission scan is simultaneously obtained with an
array of MR sequences
Dixon or UTE sequences or both for AC of the PET
data
T2 Fluid-attenuated inversion recovery sequence to
decide on the extent of vascular lesions and atrophy
Protocol of PET/MR examination
29. T2 turbo spin-echo sequences to give optimal
contrast to infratentorial structures and to evaluate
atrophy
Susceptibility-weighted sequence to detect
microbleeds
T1-magnetization–prepared rapid acquisition gradient
echo sequence for further, also quantitative,
anatomical imaging and potential morphometric
analysis.
Protocol of PET/MR examination
30. Left two columns, represent amyloid PET/MR overlay together with the z-
score map illustrating pathologic neocortical amyloid plaque burden (AD,
DLB) or normal tracer uptake (VaD)
Middle column, the corresponding transverse anatomical T1-magnetization–
prepared rapid acquisition gradient echo (MPRAGE) MR slice.
Right two columns, the corresponding transverse slices of other imaging
modalities demonstrating biparietotemporal glucose consumption deficits
(AD, DLB) or periventricular vascular lesions (VaD).
31. Severe bilateral
hippocampal atrophy
evident by severely
reduced hippocampal
volume (white arrows)
(Left more than right) on
Axial MRI images (A)
With prominent bilateral
frontal and temporal
hypometabolism on axial
fused PET MRI images
(white arrowhead) (B
and C). Note preserved
parietal metabolism on
axial and sagittal fused
PET MRI images (white
thick arrows) (D)
32. By obtaining all required imaging and biomarker
information within one session, not just an improved
convenience to the patients and their caregivers but
also to the referring doctors is anticipated.
Furthermore, combined PET/MRI is expected to
improve the diagnostic quality of both modalities by
allowing simultaneous image data acquisition as well
as a simplified and more accurate (owing to the
perfect match between the PET and MRI data) image
data analysis.
Advantages of PET/MRI
33. Head movements during data acquisition can be
online monitored by MRI, allowing for improved
motion correction of the PET data.
Further, the MR information can be used to correct
PET data for atrophy and partial volume effects.
Also, PET tracer uptake quantification can be
improved by considering MRI-derived information on
lean body mass, by creating an image-derived arterial
input function, as well as by considering factors
influencing brain tracer supply, like cerebral blood
flow.
Advantages of PET/MRI
34. Vice versa, the testing and evaluation of new MR
techniques can be improved by validating them
against simultaneously acquired PET gold standard
techniques. Examples of that are ASL, which is tested
in patients with dementia as a substitute for [18F]
FDG, or quantitative susceptibility mapping as a
potential substitute for amyloid PET tracers.
Advantages of PET/MRI
37. For dementia imaging, there are promising new PET
tracers as well as MR sequence developments.
For the PET component, the new emergence of tau
tracers and α-synuclein tracers is attractive, as they
will increase the possibilities to visualize different
histopathologic hallmarks of different underlying
dementias.
Future Potential of PET/MRI in
Dementia Diseases
38. Regarding newer potential MR techniques, especially
diffusion-tensor imaging (DTI), resting-state
functional MRI (rs-fMRI), and perfusion imaging are
considered promising candidates to improve
dementia diagnosis.
DTI maps showing white matter fiber integrity are
able to provide models of structural brain
connectivity, features that are often disturbed in
neuro-degenerative diseases.
Rs-fMRI may provide complementary information
about functional connectivity and allow functional
cerebral network analysis.
39. Perfusion MRI, either traditionally using contrast-
enhancement or arterial spin labeling (ASL), is
another attractive approach.
In combination with amyloid PET tracers, at least in
principle, the collection of information on both
biomarker categories (amyloid load and neuronal
injury) in AD within one session is possible
40. Novel PET tracers especially targeting DATs and α-
synuclein are in development, potentially opening the
way for a wider use of PET and PET/MRI as first-line
imaging in these neurodegenerative diseases.
Future Potential of PET/MRI in
Parkinsonian Syndromes
41. For MRI, standard anatomical imaging as currently
employed in most situations to detect specific
atrophy patterns for different atypical parkinsonian
syndromes might be enriched in the future by routine
voxel-based morphometry and new techniques to
detect and quantify white matter fiber degeneration
and structural connectivity deficiency (DTI), and iron
accumulation, for instance in midbrain or striatal
areas (iron mapping)
42. Future Potential of PET/MRI in Other
Neurodegenerative Diseases
There are promising new developments regarding
new PET tracers and novel MR sequences to improve
imaging of these diseases.
Some of the new emerging PET tracers target
neuroinflammatory processes known to occur in HD
or ALS,
whereas others include more disease-specific
processes like prion amyloid plaques in CJD.
44. The recently established combined PET/MRI
technology has a great but yet mostly unexplored
potential to improve early and differential diagnosis
of many neuro-degenerative diseases.
New emerging PET tracers, like tracers that bind to β-
amyloid, tau, or α-synuclein aggregates, as well as
new MR techniques, like DTI, rs-fMRI, or ASL, will
broaden the diagnostic capabilities of combined
PET/MRI.
45. From the current knowledge on applying combined
PET/MRI in neurodegenerative diseases, it is
concluded that there is a chance of establishing this
technique as routine first-line one-stop-shop clinical
imaging tool.
Basic research into neurodegenerative diseases and
antineurodegeneration drug testing are considered
other promising applications of combined PET/MRI